Literature DB >> 12857375

A theoretically optimized method for cord blood stem cell cryopreservation.

Erik J Woods1, Jun Liu, Karen Pollok, Jennifer Hartwell, Franklin O Smith, David A Williams, Mervin C Yoder, John K Critser.   

Abstract

The objective of this study was to develop an optimal cryopreservation method for human umbilical cord blood hematopoietic progenitor cells as evidenced by improved retention of in vivo engraftment ability and multilineage differentiation. An extended understanding of the osmometric/permeability characteristics of cord blood stem cells was accomplished by measuring permeability of the cryoprotectant dimethyl sulfoxide (DMSO) at below-ambient temperatures (10 degrees and 3 degrees C). These data were combined with previously published osmotic and permeability data and the water-NaCl-DMSO phase diagram in conjunction with a mathematical model to determine an optimal initial DMSO concentration, cooling rate, and liquid nitrogen plunging temperature. Cells cryopreserved with the theoretically optimized procedure were then compared with cells frozen using standard methods for the ability to engraft in irradiated NOD/SCID mice. The optimal procedure was determined to include a 0.7 molal (approximately 5%) DMSO concentration at a cooling rate of 4 degrees C/min, and a plunging temperature of -44 degrees C. The optimized protocol resulted in significantly higher engraftment of human CD45(+) cells (17.2 +/- 1.6% vs. 8.4 +/- 1.6%), CD19(+) B lymphocytes (11.3 +/- 1.2% vs. 5.8 +/- 1.2%), and CD34(+) cells (1.9 +/- 0.09% vs. 0.6 +/- 0.09%) compared to cells frozen using a standard method. Engraftment of CD33(+) cells was not significantly different (4.0 +/- 0.3 vs. 3.2 +/- 0.6, respectively). This study demonstrated that the use of a theoretically determined optimal cryopreservation method is superior to standard methods for maintaining UCB PCBs with multilineage repopulation potential in NOD/SCID mice.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12857375     DOI: 10.1089/152581603322023070

Source DB:  PubMed          Journal:  J Hematother Stem Cell Res        ISSN: 1525-8165


  7 in total

1.  Cryopreservation of Human Stem Cells for Clinical Application: A Review.

Authors:  Charles J Hunt
Journal:  Transfus Med Hemother       Date:  2011-03-16       Impact factor: 3.747

2.  Albumin-producing hepatocytes derived from cryopreserved F344 rat bone marrow cells transplanted in the livers of congenic Nagase's analbuminemic rats.

Authors:  Mitsuhiro Inagaki; Jun Arikura; Xiang Huiling; Xia Yan; Katsuhiko Ogawa; Shinichi Kasai
Journal:  Surg Today       Date:  2005       Impact factor: 2.549

Review 3.  Human embryonic stem cells: derivation, maintenance and cryopreservation.

Authors:  Jeoung Eun Lee; Dong Ryul Lee
Journal:  Int J Stem Cells       Date:  2011-06       Impact factor: 2.500

4.  Optimized cryopreservation method for human dental pulp-derived stem cells and their tissues of origin for banking and clinical use.

Authors:  Erik J Woods; Brandon C Perry; J Jeffrey Hockema; Lindsay Larson; Dan Zhou; W Scott Goebel
Journal:  Cryobiology       Date:  2009-06-16       Impact factor: 2.487

5.  An improved cryopreservation method for a mouse embryonic stem cell line.

Authors:  Corinna M Kashuba Benson; James D Benson; John K Critser
Journal:  Cryobiology       Date:  2007-12-10       Impact factor: 2.487

6.  Non-ideal solution thermodynamics of cytoplasm.

Authors:  Lisa U Ross-Rodriguez; Janet A W Elliott; Locksley E McGann
Journal:  Biopreserv Biobank       Date:  2012-10       Impact factor: 2.300

7.  Expansion of Human Tregs from Cryopreserved Umbilical Cord Blood for GMP-Compliant Autologous Adoptive Cell Transfer Therapy.

Authors:  Howard R Seay; Amy L Putnam; Judit Cserny; Amanda L Posgai; Emma H Rosenau; John R Wingard; Kate F Girard; Morey Kraus; Angela P Lares; Heather L Brown; Katherine S Brown; Kristi T Balavage; Leeana D Peters; Ashley N Bushdorf; Mark A Atkinson; Jeffrey A Bluestone; Michael J Haller; Todd M Brusko
Journal:  Mol Ther Methods Clin Dev       Date:  2016-12-24       Impact factor: 6.698

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.